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Background: Irritable Bowel Syndrome (IBS) is a hidden public health disease that affects up to 20% of the general
population. Although co-morbidity can affect diagnose setting and treatment of the disease, there are few studies
concerning diagnosed and registered co-morbidity for IBS patients in primary care. The aim of this study was to
analyse co-morbidity among IBS-patients compared to age- and sex-matched controls from the general population
using data from a county-wide computerized medical record system.
Methods: IBS cases were recruited from three Swedish primary health care centres during a five-years period and
controls from the same corresponding geographical areas. Co-morbidity data for IBS-patients and morbidity data
for controls were derived from a population-based Health Care Register (HCR) covering all diagnoses in primary as
well as hospital care in the region. Odds Ratios with 95% confidence intervals for morbidity in gastro-intestinal and
non-gastrointestinal diagnoses for cases with irritable bowel syndrome compared to controls were calculated
separately for each gender and diagnosis.
Results: We identified more co-morbidity among IBS patients of both sexes, compared to matched controls in the
general population. Patients with IBS were particularly more worried about having a serious disease than their
control group. The risk among male IBS-cases to get this latter diagnose was three times higher compared to the
male controls.
Conclusions: In this population based case–control study, the analysis of diagnoses from the HCR revealed a broad
spectrum of common co-morbidity and significantly more physician-recorded diagnoses among IBS-patients in
comparisons to the control group.
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GenderBackground
Irritable bowel syndrome (IBS) is a common functional
gastrointestinal disorder (FGD) which affects up to 20%
of the general population, but can be considered as a
“hidden” public health disease. IBS has been reported to
be associated with a broad variety of psychological and
physical symptoms and discomforts, as well as impaired* Correspondence: ashild.olsen.faresjo@liu.se
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reproduction in any medium, provided the orquality of life and increased use of health care resources
[1-6]. In this group of patients, a common reason for
seeking health care is fear of severe gastrointestinal (GI)
or other illness [7-9]. Adequate consideration of co-
morbidity is of vital importance for accurate diagnosis of
FGDs and choice of treatment for this patient group.
Although FGDs are not life-threatening, exclusion of
serious diseases, such as different types of gastrointes-
tinal cancer, is a major clinical challenge. The clinical
decision-making is therefore often difficult, in light of
that psychological, social and biological factors all play aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to be different in different patients and may vary over
time for the same person [5,6,10-12]. The treatments
available today are beginning to address the multifac-
torial aetiology, and cover both pharmaceutical and
non-pharmaceutical treatments, e.g. hypnotherapy and
cognitive behavioural therapy [13,14]. Contrary to se-
veral of these findings, our recent study in Swedish
primary care showed that IBS patients were not high
consumers of health care and that most IBS patients
consulted their general practitioner (GP) only for their
abdominal problems [15,16]. Other studies have shown
that approximately 50% of IBS patients from primary
care and specialist clinics have at least one co-morbid
symptom [17]. Hudson et.al reported that co-morbidity
related to IBS includes fibromyalgia, migraine, chronic
fatigue syndrome, major depression and panic disorder
[18]. Patients with one or more co-morbid complaint
tend to report more severe IBS symptoms, more mental
complaints and more illness related absenteeism than
patients without co-morbid disorders [17,19-22]. Psycho-
social factors may also influence the health care seeking
behaviours in addition to the irritable bowel syndrome it-
self. Anxiety and depression have been reported being
more common in IBS patients than healthy controls.
However, the causal relationship between IBS and psycho-
social factors are still unknown [5,23].
Although co-morbidity can affect diagnose setting and
treatment of IBS, there are few studies concerning diag-
nosed co-morbidity for IBS patients in primary care [24].
This study sets out to examine the 8-year prevalence of
co-morbidity, morbidity, and worry about serious disease
according to physician diagnoses among IBS-patients
compared to controls from the general population using
data from a regional Health Care Register (HCR) cove-
ring all levels of care. The research hypotheses are that
IBS patients are more burdened by co-morbidity and
disease worry than the general population.
Methods
This present study is a part of a larger population-based
case–control study [5,15,16]. Cases were patients from a
Swedish primary health care (PHC) area receiving an
IBS diagnose (ICD-10-P code K-58-p) according to
Manning/Rome II diagnostic criteria [25] during a 5-
year period (1997–2001). For all primarily identified IBS
cases, the medical records were checked to ensure that
there had not been any earlier IBS diagnosis. We found
115 cases with a prior confirmed diagnosis in the med-
ical records (before 1997).Furthermore, seven IBS cases
patients (three males and four females) died during the
follow-up and four had a sheltered and non accessible
medical record. Consequently, these cases were exclu-
ded. Controls were randomly selected from the censusregister for the population in the same geographical area
using matching criteria for age and sex. Prior to the sur-
vey, a check was made to ensure that individuals in the
control group did not have any registered IBS diagnosis
at baseline. Data on co-morbidity, morbidity and worry
about serious disease during an 8-year period for cases
and controls were collected from a regional Health Care
Register (HCR). Disease worry was defined by the cor-
responding ICD-10-P diagnose code Z71.1.
Study population
The study was performed in Linköping (population
143.000), south-east of Sweden. The primary study po-
pulation was defined by the geographical area covered
by three urban PHC centres that provided PHC services
to approximately 40.000 inhabitants. Before the investi-
gation started, a pilot study was performed to develop a
data registration form at one PHC centre. The medical
records of fifty IBS cases with the code number K-58-p
according to ICD-10-P were used for this purpose.
IBS cases were identified retrospectively from medical
records at the three selected PHC centres for the period
between 1/1 1997 and 31/12 2001. The medical records
are not freely available for everyone, access is given after
an ethical approval to researchers. Diagnosis, date of
diagnosis, symptoms and data on number of health care
visits, reason for consulting GP and demographic data
were available in the medical records. In this case–con-
trol study, only IBS cases in working ages between
18–65 years were included, which resulted in N = 515
IBS cases in all. Through the local census population
register, 4.500 sex-matched controls in the correspond-
ing ages were randomly selected. The number of con-
trols was chosen proportionally following the size of the
actual population living in each of the three PHC areas
(i.e. 2.100, 1.500 and 900 controls from the respective
PHC areas). We found that 493 out of 515 patients and
2.773 out of 4.500 controls were registred in the HCR.
The analysis is based on 493 patients and 2.773 controls.
Data collection
To collect data on co-morbidity on 493 IBS cases and
morbidity on 2773 controls, we used a regional HCR.
This specifik database is not freely available for every-
one, access is given after an ethical approval only to re-
searchers from the university and employees from the
county concil. This system is based on a unique personal
code to birth date and gender of all inhabitants in the
region. The database comprises diagnoses from primary
care, hospital outpatient and hospital inpatient care was
at the time of the study the only register of this type in
Sweden [26]. ICD 10-codes were used for identification
of morbidity in cases and controls during the period
1999–2007, two years after the first diagnosed cases
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All diagnostic codes were assigned by the GP or attending
physician. The diagnoses were extracted from the
HCR using a case-finding algorithm that retrospectively
searched the register from 1/1/1999 to 31/12/2007.
Statistical analysis
All data were stored in a common database and statisti-
cally analysed using the SPSS version 17.0 program
(SPSS Inc., Chicago, IL, USA. 8-year prevalence of ge-
neral and GI-specific morbidity was used as measure for
the comparisons between cases and controls. 8-year
morbidity prevalence was defined as having received
specified diagnoses during the period 1999–2007. The
Odds Ratios (OR) and 95% confidence intervals (CI) for
co-morbidity was calculated separately for males and fe-
males and for IBS-patients and controls. In the HCR,
the following case definition was applied: the first con-
tact with health care services with different diagnoses
during the period studied (1999–2007) was regarded as
a case, the algorithm captured the cases (one case = one
patient) regardless of whether the disorders of interest
constituted the main or secondary diagnosis, and it also
specified the health care level at which the patient was
diagnosed.
Ethical approval
The Ethical Committee at the Faculty of Health Sciences,
Linköping University, Sweden, approved this study in
2002 and 2007 (Dnr M93-07).
Results
In this study population, 72% of the IBS cases were fe-
male and more than 50% were below the age of 45 at
baseline the controls were age and sex matched. See
Table 1. The 8-year general morbidity was higher among
IBS-patients in comparison to the control group. Also
the prevalence of specific GI morbidity was higher
among cases of both sexes compared to their control
groups.Table 1 IBS cases (n = 493) and controls (n = 2773)
divided in sex and age
IBS cases Controls
n % n %
Sex:
Male 140 28.0 1292 46.5
Female 353 72.0 1481 53.4
Age:
18 to 24 40 11.3 435 15.7
25 to 44 147 41.6 1171 42.2
45 to 64 166 47.0 1167 42.0The ICD-diagnosis “worry about serious disease” Z71.1
was more common among IBS cases of both sexes com-
pared to their controls; more than three times frequent
among males OR = 3.30 (95% CI 1.93-5.66) and almost
twice as common among females OR = 1.62 (95% CI
1.21-2.18), see Table 2.
In general, females with an IBS diagnosis had more
recorded co-morbidity during the 8-year period than
male IBS-patients. In particular, females were to a larger
extent than female controls diagnosed with psychiatric
disorders (depression, anxiety and worries) and diag-
noses related to musculoskeletal problems and pain
(arthritis, myalgia/rheumatism UNS, migraine/headache,
pain and suffering UNS). Thyroid hormone problems,
asthma/allergy, hypertension, high cholesterol, kidney
problems and infection in the urinary tract were also
slightly more registered among females with an IBS
diagnosis compared to females in the control group.
This pattern was also seen concerning cancer and re-
spiratory tract infections, as well as fatigue and malaise,
see Table 2. Male cases showed almost the same pattern
as the female did with small exceptions. Male IBS-
patients had slightly more stress diagnoses compared to
their control group and less cancer diagnoses.
Almost all IBS cases had additional unspecific FGD
diagnoses registered in the HCR during the 8-year
period. However, the female IBS cases were also diag-
nosed with more cancer in the abdominal tract than
their control group as well as more inflammatory bowel
disease. Male cases had on the other hand more hae-
morrhoids and rectal abscesses, lactose intolerance and
celiac disease than their control group, see Table 3.
Discussion
It is well known that broad spectrums of diagnostic pro-
cedures are needed to exclude other conditions when
IBS is suspected, due to an overlap between different GI
diseases. Studies have also previously reported GI and
other co-morbidity among IBS cases; but many of these
studies have been performed among IBS health care
seekers [27-31] and only a few have been based on a
population-based design [23,24]. The main findings of
this study are that IBS cases more often receive the diag-
nosis “worry about having a serious disease” (ICD-10
Z71.1) than their control group. This particular ICD-
diagnosis is established and used when an individual
consult his physician claiming fears of having a serious
disease, but after doctors’ examination no further diag-
nose could be set. The risk among male IBS-cases to get
this diagnosis was three times higher compared to the
male controls. As also reported from previous studies,
IBS cases of both sexes had in general more diagnoses
recorded in the HCR compared to matched controls in
the general population. However, the design of the study
Table 2 Eight-year prevalence of non-gastrointestinal morbidity in IBS-patients and controls
Diagnosis Female IBS




cases N = 140
Male controls
N = 1292
n % n % OR CI 95% n % n % OR CI 95%
Worry about serious disease 73 21.1 205 14.0 1.62 1.21–2.18** 20 14.3 62 5.1 3.30 1.93–5.66***
Cardiovascular complaints
Stroke, chest pain UNS
180 51.1 288 19.4 4.31 3.37–5.51*** 89 64.1 331 26.1 5.06 3.51–7.31***
Hypertension 90 25.5 226 15.3 1.90 1.44–2.51 ** 36 26.0 232 18.1 1.58 1.05–2.37**
Diabetes 1 30 8.5 90 6.1 1.43 0.93–2.21 12 8.6 129 10 0.84 0.45–1.57
High Cholesterol 43 12.2 95 6.4 2.02 1.38–2.96 ** 33 23.6 151 11.7 2.33 1.52–3.57***
Obesity 16 4.5 67 4.5 1.00 0.57–1.75 7 0.5 42 3.3 1.56 0.69–3.56
Thyroid diseases 52 15.0 133 8.9 1.75 1.24–2.47 ** 5 3.6 55 4.3 0.83 0.33–2.11
Asthma/allergy 114 32.2 373 25.1 1.42 1.10–1.83 * 38 27.1 228 18.0 1.74 1.16–2.59*
Eczema 58 16.4 123 8.3 2.17 1.55–3.04*** 19 13.6 86 6.6 2.20 1.29–3.74*
Obstructive lung disease 10 2.8 22 1.5 1.93 0.91– 4.12 8 5.7 12 1.0 6.46 2.60–16.10*
Arthritis 51 14.4 92 6.2 2.55 1.77–3.67*** 22 15.7 79 6.1 2.86 1.72.4.72*
Musculoskeletal problems 104 29.5 263 18.0 1.93 1.48–2.52*** 40 28.6 183 14.5 2.42 1.63–3.61***
Myalgia/rheumatism UNS 211 60.0 573 28.7 2.35 1.86–2.99*** 65 46.4 345 27.0 2.38 1.67–3.39***
Pain and suffering UNS 48 14.1 120 8.1 1.78 1.25–2.55** 19 13.6 72 5.6 2.66 1.55–4.56**
Migraine/headache 142 40.2 310 21.0 2.54 1.99–3.25*** 39 28.1 135 10.4 3.31 2.20–4.99***
Mental problems 2 213 60.0 275 19.1 6.67 5.19–8.56*** 47 33.6 194 15.0 2.86 1.81–3.45***
Stress 68 19.3 244 16.5 1.20 0.90–1.63 19 14.0 97 7.5 1.93 1.14–3.27*
Tinnitus 15 4.2 44 3.0 1.45 0.80–2.64 5 3.6 38 3.0 1.22 0.47–3.20
Eating disorder 1 0.3 11 0.7 0.38 0.05–2.95 3 2.1 1 0.01 28.27 2.92–273.6***
Cancer 14 4.1 16 1.1 3.78 1.83–7.83*** 1 0.7 5 0.4 1.85 0.22–15.96
Cold, flu/respiratory infections 56 16.1 121 8.2 2.12 1.51–2.98*** 20 14.3 55 4.3 3.75 2.17–6.47***
Infection in the urinary tract 48 14.1 84 6.1 2.62 1.80–3.81*** 16 11.4 28 2.2 5.82 3.08–11.06***
Disease in the kidney 11 3.1 6 0.4 7.91 2.90–21.53** 3 2.1 12 0.9 2.34 0.65–8.38
Gynaecological/pregnancy/
3Urological/prostate problems4
19 5.4 64 4.3 1.26 0.74 –2.13 3 2.1 9 0.7 3.12 0.83–11.67
Fatigue and malaise 117 33.1 225 15.2 2.77 2.13–3.60*** 31 22.1 101 8.0 3.35 2.14–5.25***
Psychosocial factors in daily life 5 1.4 11 0.7 1.85 0.87–3.92 2 1.4 10 0.8 1.85 0.21–4.66
Investigation of serious illness 16 4.5 19 2.0 3.65 1.86–7.18*** 1 0.7 7 0.5 1.32 0.16–10.83
Miscellaneous diseases 185 52.4 362 24.4 3.40 2.68–4.33*** 52 37.1 266 21.1 2.80 1.58–3.29***
1. Both insulin dependent and insulin independent diabetes. 2. Includes anxiety, depression, sleeping problems, worries etc. 3. Concerns women 4. Concerns
men. ***p = 0.001, **P = 0.01, *p = 0.05.
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recorded co-morbidity was a cause or consequence of
IBS. Neither did the chosen study design allow us to fur-
ther analyse the findings that IBS patient seemed to be
more worried of having a serious disease, than their con-
trols. This was an additional finding in this study and
more research is warranted on this issue.
Non-GI symptoms form one important part of IBS pa-
tients’ complaint panorama, which affects diagnose set-
ting and treatment of the disease [29,32]. Our previous
results pointed out that non-GI co-morbidity affec-
ted the use of heath care as well as a strong predictor
for follow-up visit to the GP among IBS patients [16].Higher frequencies of anxiety and depression as well as
sleeping problems, have previously been recognized as
factors associated with IBS diagnosis [23,33-39]. IBS and
anxiety disorders are reactive to stress and are likely to
involve serotonergic disturbance, which include anti-
cipatory worries and avoidance behaviours that impair
quality of life as well as functioning in everyday life
[5,40-42]. This complex form of co-morbidity probably
involve psychological and physiological processes that
trigger each other and form a spiral between the two
types of disorders, completely independent of sex. Fa-
tigue and malaise could be a result of dealing with
both psychological and physiological symptoms and
Table 3 Eight-year prevalence of gastrointestinal morbidity in IBS-patients and controls
Diagnosis Female IBS




cases N = 140
Male controls
N = 1292
n % n % OR CI 95% n % n % OR CI 95%
Reflux complaints (GERD) 73 21.1 77 5.5 4.75 3.37–6.71*** 21 15.0 70 5.4 3.08 1.83–5.20***
Complaints with known ulcer 5 1.4 5 0.3 4.24 1.22–14.73* 4 2.9 11 1.0 3.42 1.08–10.90*
Functional dyspepsia 134 38.1 128 8.6 6.47 4.88–8.57*** 53 35.7 92 7.1 7.94 5.32–11.88**
Inflammatory bowel disease 28 7.9 62 4.2 1.97 1.24–3.13*** 6 4.3 41 3.2 1.37 0.57–3.28
Diverticulitis in the bowel 33 9.3 12 0.8 12.62 6.44–24.71 *** 10 3.6 55 4.3 9.86 4.03–24.13***
Haemorrhoids and rectal abscesses 25 7.1 67 4.5 1.61 1.00–2.59 22 15.7 58 4.5 3.97 2.35–6.71***
Liver diseases 3 0.8 5 0.3 2.53 0.60–10.65 0 0 17 1.3 – –
Gallstone, gallbladder inflammation
and other diseases in the
gallbladder area
30 8.5 55 3.7 2.41 1.52–3.82** 8 5.7 20 1.5 3.85 1.67–8.92**
Lactose intolerance 1 0.3 9 0.6 0.46 0.06–3.68 2 1.4 2 0.2 9.35 1.31–66.88*
Coeliac disease 4 1.1 13 0.9 1.39 0.42–3.99 3 2.1 4 0.3 7.05 1.56–31.83*
Irritable bowel syndrome 1 30 8.5 8 0.5 – – 6 4.3 5 0.4 – –
Gastroenteritis 4 1.1 5 0.3 3.38 0.90–12.66 1 0.7 5 0.4 1.85 0.21–15.96
Cancer in the abdominal tract 2 8 2.3 5 0.3 6.84 2.26–21.05 *** 2 1.4 6 0.5 2.55 0.62–15.54
Benign tumours in the abdominal
tracts
18 5.1 9 0.6 8.79 3.92–19.73 *** 4 2.9 10 0.8 3.77 1.17–12.18*
Miscellaneous gastrointestinal
complaints
6 1.7 18 1.2 1.40 0.55–3.57 6 4.3 26 2.0 2.18 0.88–5.39
1. For IBS cases, this is a renewed diagnose set after 2001, for the controls it is new diagnose, set after 2001. 2. Includes cancer diagnose in colon, ventricle and
rectum. ***p = 0.001, **p = 0.01, *p = 0.05.
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frequent among the IBS cases. Fatigue has also been
identified as the most common somatic symptom as-
sociated with IBS in India [30].
IBS patients were found to suffer more frequently
from headache and migraine than their controls, which
other studies confirm [29,43,44]. This might due to se-
vere IBS symptoms or the other way around, i.e. that
these particular co-morbidities contribute to worsen
the IBS symptoms through unknown mechanisms. The
brain-gut axis could be involved as well as neuroendo-
crine and neuroimmune interactions [43,45,46]. Fibro-
myalgia is the most frequently investigated co-morbidity
of IBS [29,47,48]. In this study, fibromyalgia was re-
cognized as co-morbidity only among females. Very few
had a registered diagnosis of fibromyalgia, but myalgia/
rheumatism UNS occurred more frequently among all
IBS cases compared to the control group. Additionally,
musculoskeletal problems, arthritis and pain and suffer-
ing UNS were significantly more common among IBS
cases of both sexes. One could hypothesize that all these
pain-related complaints might lead to a larger consump-
tion of analgesics resulting in damage in the mucosa in
the GI canal which might worsen the existing symptoms
or new GI symptoms will occur. Treatment of, for in-
stance, arthritis often includes a short-term use of non-steroidal anti-inflammatory drugs (NSAID) [49]. Previ-
ous results from the present research program showed
that IBS cases of both sexes consumed significantly
more analgesics than their controls did [50]. Registered
diagnoses of thyroid disease, asthma, allergy, infections
in the urinary tract as well as cardiovascular problems
were more frequent among the IBS cases. The majority
of co-morbidity diagnoses in this study were set after the
initial IBS diagnosis. One can speculate if IBS diagnosis
is a marker for other diseases or simply a reason for
follow-up visits to health care were these co-morbidity
are discovered. These observations of co-morbidity in
several extraintestinal organ systems might raise the sus-
picion that the physician’s specialisation influences the
diagnosis of morbidity in relation to IBS. A hypothesis is
that medical subspecialisation is responsible for an arti-
ficial separation of one and the same disease, i.e. a spe-
cialist in gastroenterology will use the diagnosis IBS, a
rheumatologist fibromyalgia, etc. [51]. Therefore it is im-
portant for physicians to exclude other organic diseases
and refer IBS patients with somatic co-morbid symp-
toms to specialists within that particular area. In other
words, it is important to arrive at the correct diagnose
in order to be able to provide an adequate treatment.
Various GI co-morbidity were frequent more common
in IBS cases such as functional dyspepsia (FD) and reflux
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IBS-typical and FD typical symptoms can be found in in-
dividuals with FGD [32]. Moreover, the abdominal com-
plaints in individuals with a FGD often change over time
resulting in variations of predominant symptoms in al-
most the majority of the patients during a year. This cir-
cumstance may explain the high frequency of unspecific
different FGD diagnoses within the patient group almost
every case had two or more FGD-UNS diagnosis previ-
ous to the IBS diagnosis. One hypothesis is that the mo-
tility disturbance of the gastrointestinal tract is involved
in the complex pathophysiology of GERD, FD and IBS
might result from a common neuromuscular dysfunction
[52-54]. Other, GI diagnoses seen were inflammatory bo-
wel disease, diverticulitis, gallstone, gallbladder inflam-
mation and other diseases in the gallbladder area as well
as haemorrhoids and rectal abscesses. The latter was the
only diagnosis where a gender difference could be seen,
with more males suffering from these complaints. In
consideration of the Rome criteria, an organic disease
must be excluded before the diagnosis of IBS is set.
However, due to the relapsing character of ulcerative
colitis and Chron’s disease, many patients have long-
standing remission without any sign of active inflamma-
tion and in these patients an increased prevalence of
IBS-like symptoms have been found [55]. One hypothe-
sis is that IBS subgroups with post-infectious IBS might
share pathophysiological mechanism with IBD patients
in remission who suffer from IBS-like symptoms, which
might explain the frequency of IBD diagnoses among
the cases [55-57]. Although, all IBD diagnosis was set
after the initial IBS diagnose, otherwise these cases
would have been excluded from the study at baseline.
There seems to be some increase in cancers in the GI-
tract for female IBS-cases in this study, one must be very
careful when interpret such associations, because it is
few cases and consist of three GI-cancer diagnoses. Be-
nign tumours in the abdominal tract were also seen
more frequently among cases of both sexes compared to
their control group.
One major limitation of this case–control study is that
the design does not permit to draw conclusions about
whether a recorded co-morbidity is causally related to
IBS. However, the study also has several strengths. One
strength is that it is based on computerized Health Care
Records (HCR) for all inhabitants linked by birth date
and sex. The same personal code is used for all visits
and diagnoses in Health Care registers (HCR). An indi-
vidual can thus be followed retrospectively or prospect-
ively through the health care system using this personal
code. The health care institution where the patient was
diagnosed represents all health care levels—primary care,
outpatient hospital care, and/or inpatient hospital care
which gives a more complete panorama of the healthcare. Other strengths of this study are that our inclusion
method gains reliability through being very general and
covering a span of several years and that the number of
included patients is high tending to level out possible
misclassification within the groups defined as patients.
However, a study of the quality and content of the Swed-
ish Hospital Discharge Register indicates 95% coverage
of main diagnostic codes in inpatient care in this region
in 1986 and 98% in 2002 [58]. Validation of HCR and
other administrative data has shown high specificity in
registers covering all types of health care [26,59]. But a
constraint for register data is that misclassifications do
occur, including cases that are not recorded because they
are overlooked or given incorrect clinical codes. ICD
code registration could vary between physicians and
health care centers and also between diagnoses [60].
Nevertheless it can be assumed that the data used in this
study based on a HCR has high reliability, the majority
of the patients and controls had registred the same diag-
nosis code in HCR several times during the study period,
so we could be certain of the accuracy of the diagnose
settning.
Moreover, the study was based on a population-based
case–control design [61]. Further, prior to the survey, a
check was made to ensure that individuals in the control
group did not have any registered IBS diagnose during
the period studied. We calculated the number of controls
to this study in accordance with the epidemiological well-
established principle; when having a case–control study,
every identified case should at least have two or preferably
at least three controls each from the general population.
Another possible limitation in using IBS diagnoses from
medical records, as we have in this study, is the depend-
ence on the GP’s ability to make the correct diagnosis.
However, studies have shown that GPs rarely misdiagnose
patients, and in particular not IBS [62-64]. There could,
on the contrary, rather be a tendency to under-diagnosing
of these complaints in primary care. Medical records in
primary care in Sweden are generally regarded as a reliable
source of such kinds of data collection since the PHC
centres have an overall responsibility for the PHC in a
catchment area, and therefore are required to regularly re-
port morbidity patterns based on structured diagnosis.
This weakness is the same in the case of most clinical
research utilizing data from more than one health care
provider [65,66].
Conclusions
IBS patients seem to worry about serious diseases more
than controls in the general population. They also seem
to be burdened with more physician-diagnosed co-
morbidity compared to age- and sex-matched controls
in the general population. The casual direction of this
co-morbidity needs to be further investigated.
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